Research Article

Amygdalin (Vitamin B17) Effect on Glioblastoma: Focus on Oxidant Capacity and Antioxidant Status

Volume: 2 Number: 2 August 29, 2024
EN

Amygdalin (Vitamin B17) Effect on Glioblastoma: Focus on Oxidant Capacity and Antioxidant Status

Abstract

Objective: Amygdalin (Vitamin B-17) is a type of vitamin, naturally found in many fruits and plants. The aim of the study was the evaluation of Amygdalin effect on the oxidant capacity and oxidant status of the T98G cancer cells. A T98G cell line was used in the study. Cell viability and oxidative stress evaluation were done. Methods: Amygdalin was used at 1, 4, and 8 µg/mL doses. TAC and TOS values were measured. Results: According to the result, amygdalin 8 µg/mL shows the highest anticancer effects. TAC level was 3.2 Trolox Equiv/L and TOS was 3.6 H2O2 Equiv/L. Conclusion: Vit B17 can increase oxidative stress in T98G cells and decrease cell viability

Keywords

References

  1. Altinoz, M. A., Yilmaz, A., Taghizadehghalehjoughi, A., Genc, S., Yeni, Y., Gecili, I., & Hacimuftuoglu, A. (2022). Ulipristal-temozolomide-hydroxyurea combination for glioblastoma: In-vitro studies. Journal of Neurosurgical Sciences. 68(4):468-481
  2. Bauernfeind, F. G., Horvath, G., Stutz, A., Alnemri, E. S., MacDonald, K., Speert, D., ... & Latz, E. (2009). Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. The Journal of Immunology, 183(2), 787–791.
  3. Carter, J. H., McLafferty, M. A., & Goldman, P. (1980). Role of the gastrointestinal microflora in amygdalin (laetrile)-induced cyanide toxicity. Biochemical Pharmacology, 29(3), 301–304.
  4. El-Desouky, M. A., Fahmi, A. A., Abdelkader, I. Y., & Nasraldin, K. M. (2020). Anticancer effect of amygdalin (vitamin B-17) on hepatocellular carcinoma cell line (HepG2) in the presence and absence of zinc. Anti-Cancer Agents in Medicinal Chemistry, 20(4), 486–494.
  5. Fernald, K., & Kurokawa, M. (2013). Evading apoptosis in cancer. Trends in Cell Biology, 23(12), 620–633.
  6. Gogolin, S., Ehemann, V., Becker, G., Brueckner, L. M., Dreidax, D., Bannert, S., ... & Westermann, F. (2013). CDK4 inhibition restores G₁-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage. Cell Cycle, 12(7), 1091–1104.
  7. Jaszczak-Wilke, E., Polkowska, Ż., Koprowski, M., Owsianik, K., Mitchell, A. E., & Bałczewski, P. (2021). Amygdalin: Toxicity, anticancer activity and analytical procedures for its determination in plant seeds. Molecules, 26(8), 2253.
  8. Kafagi, A. H., Li, A. S., Jayne, D., & Brix, S. R. (2024). Anti-GBM disease in pregnancy. BMJ Case Reports CP, 17(4), e257767.

Details

Primary Language

English

Subjects

Medical Pharmacology, Cancer Therapy (Excl. Chemotherapy and Radiation Therapy)

Journal Section

Research Article

Publication Date

August 29, 2024

Submission Date

July 29, 2024

Acceptance Date

August 26, 2024

Published in Issue

Year 2024 Volume: 2 Number: 2

APA
Genç, S., Karabulut, K., Niğde, E., Aydin, Y. E., Aydın, B., Aydın, A. E., & Taghizadehghalehjoughi, A. (2024). Amygdalin (Vitamin B17) Effect on Glioblastoma: Focus on Oxidant Capacity and Antioxidant Status. Recent Trends in Pharmacology, 2(2), 75-78. https://doi.org/10.62425/rtpharma.1523732
AMA
1.Genç S, Karabulut K, Niğde E, et al. Amygdalin (Vitamin B17) Effect on Glioblastoma: Focus on Oxidant Capacity and Antioxidant Status. Recent Trends in Pharmacology. 2024;2(2):75-78. doi:10.62425/rtpharma.1523732
Chicago
Genç, Sıdıka, Kübra Karabulut, Esmanur Niğde, et al. 2024. “Amygdalin (Vitamin B17) Effect on Glioblastoma: Focus on Oxidant Capacity and Antioxidant Status”. Recent Trends in Pharmacology 2 (2): 75-78. https://doi.org/10.62425/rtpharma.1523732.
EndNote
Genç S, Karabulut K, Niğde E, Aydin YE, Aydın B, Aydın AE, Taghizadehghalehjoughi A (August 1, 2024) Amygdalin (Vitamin B17) Effect on Glioblastoma: Focus on Oxidant Capacity and Antioxidant Status. Recent Trends in Pharmacology 2 2 75–78.
IEEE
[1]S. Genç et al., “Amygdalin (Vitamin B17) Effect on Glioblastoma: Focus on Oxidant Capacity and Antioxidant Status”, Recent Trends in Pharmacology, vol. 2, no. 2, pp. 75–78, Aug. 2024, doi: 10.62425/rtpharma.1523732.
ISNAD
Genç, Sıdıka - Karabulut, Kübra - Niğde, Esmanur - Aydin, Yunus Emre - Aydın, Beyzanur - Aydın, Alperen Enes - Taghizadehghalehjoughi, Ali. “Amygdalin (Vitamin B17) Effect on Glioblastoma: Focus on Oxidant Capacity and Antioxidant Status”. Recent Trends in Pharmacology 2/2 (August 1, 2024): 75-78. https://doi.org/10.62425/rtpharma.1523732.
JAMA
1.Genç S, Karabulut K, Niğde E, Aydin YE, Aydın B, Aydın AE, Taghizadehghalehjoughi A. Amygdalin (Vitamin B17) Effect on Glioblastoma: Focus on Oxidant Capacity and Antioxidant Status. Recent Trends in Pharmacology. 2024;2:75–78.
MLA
Genç, Sıdıka, et al. “Amygdalin (Vitamin B17) Effect on Glioblastoma: Focus on Oxidant Capacity and Antioxidant Status”. Recent Trends in Pharmacology, vol. 2, no. 2, Aug. 2024, pp. 75-78, doi:10.62425/rtpharma.1523732.
Vancouver
1.Sıdıka Genç, Kübra Karabulut, Esmanur Niğde, Yunus Emre Aydin, Beyzanur Aydın, Alperen Enes Aydın, Ali Taghizadehghalehjoughi. Amygdalin (Vitamin B17) Effect on Glioblastoma: Focus on Oxidant Capacity and Antioxidant Status. Recent Trends in Pharmacology. 2024 Aug. 1;2(2):75-8. doi:10.62425/rtpharma.1523732

Cited By